Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aveo receives complete response for RCC therapy

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) received a complete response letter for an NDA for tivozanib to treat advanced renal cell carcinoma (RCC). According

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE